Drug-Drug Interaction Study of MRA in Patient With Rheumatoid Arthritis (RA)
Not Applicable
Completed
- Conditions
- Rheumatoid Arthritis
- Registration Number
- NCT00144560
- Lead Sponsor
- Chugai Pharmaceutical
- Brief Summary
This is an open-label, clinical pharmacology study to investigate drug-drug interaction in patients with RA.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 31
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method 20% improvement based on the ACR criteria compared with the baseline value. throughout study
- Secondary Outcome Measures
Name Time Method Time courses taken from baseline values for DAS28, for ACR20%, 50%, and 70% improvement, and for each ACR core set variable. Week 0,Week 1, Week 2
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What are the molecular mechanisms of MRA in rheumatoid arthritis drug interactions?
How does MRA compare to standard-of-care DMARDs in RA patients with comorbidities?
Which biomarkers correlate with MRA efficacy in RA drug-drug interaction studies?
What adverse events are associated with MRA in RA patients on concomitant medications?
Are there combination therapies involving MRA and biologics for RA treatment?